Catto JWF, Daneshmand S, Zaucha R, Tran B, Master V, Lotan Y, Pignot G, Tubaro A, Shimizu N, Vasdev N, Lee EK, Procopio G, Galanternik F, Fischer DS, Levin TG, Zhang J, Thomas S, Stone N, Triantos S, Beeharry N. A0591 Longitudinal assessment of urine tumor DNA in high-risk non-muscle invasive bladder cancer patients. European Urology. 2026;89:10.1016/s0302-2838(26)00642-1
Harris W, Shirley S, Liow E, Tan A, Jacobs C, Fong P, Fu S, Tan E, Waldron N, Weickhardt A, Wong S, Tran B, Lawrence N. Real-World Outcomes in Advanced Clear Cell Renal Cell Carcinoma: A Retrospective Analysis Comparing New Zealand and Australian Cohorts.JCO Global Oncology. 2026;12(3):10.1200/go-25-00384
Anton A, Steer C, Arasaratnam M, Torres J, Weickhardt A, Warren M, Mislang ARA, Azad AA, Linton A, Smith A, Rai S, Hong W, Gibbs P, Tran B. Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro). ESMO Real World Data and Digital Oncology. 2026;11:10.1016/j.esmorw.2025.100677
Pan HY-C, Shi W, Mulholland C, Conduit C, Tran B, Hitchen N, Lawrentschuk N, Thomas B. Primary retroperitoneal lymph node dissection for clinical stage IIA/B metastatic seminoma: A multi-centre Australian experience.Journal of Clinical Oncology. 2026;44(7_suppl):10.1200/jco.2026.44.7_suppl.601
2026;
Tran B, Voskoboynik M, Kim S-W, Lemech C, Carcereny E, Rha SY, Ahn M-J, Felip E, Lee KH, Castañón Álvarez E, Yang JC-H, Ascierto PA, Provencio Pulla M, Kondo S, Kuboki Y, Freeman D, Song X, Blando J, Eck S, Song FJ, Tang Z, Kuziora M, Gainer SD, Mitchell P, Asare J, Ayyoub A, Achour I, Subramaniam DS, Im S-A. Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody.Clinical Cancer Research. 2026;:10.1158/1078-0432.ccr-25-3447
Conduit C, Bagrodia A, Hamilton RJ, Feldman DR, Tran B. Optimal Management of Stage II Seminoma: Preventing Harm While Preserving Cure. JCO Oncology Practice. 2026;22(2):10.1200/op-25-00252
Lemelin A, Zarba M, Takemura K, Wells JC, Chehade REH, Donskov F, Porta C, De Velasco G, Davis ID, Wood LA, Pal SK, Hansen AR, Tran B, Bjarnason GA, Li H, Kanesvaran R, Powles T, McKay RR, Choueiri TK, Heng DYC. Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC). Clinical Genitourinary Cancer. 2026;24(1):10.1016/j.clgc.2025.102484
Daneshmand S, Zaucha R, Catto JWF, Tran B, Master V, Lotan Y, Pignot G, Tubaro A, Shimizu N, Vasdev N, Lee EK, Procopio G, Galanternik F, Crow L, Deprince K, Naini V, Triantos S, Baig M, Zhu W, Maranchie JK. Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. European Urology. 2026;89(2):10.1016/j.eururo.2025.09.4152
Chow KVC, Conduit C, O’Haire S, Kuchel A, Wong S, Grimison P, Weickhardt A, Pranavan G, Lynam J, Bastick P, Goh J, Sengupta S, Smith A, Liow E, Campbell D, Wong M, Zlatic K, Gibbs P, Tran B, Gan CL. Extracranial, Extragonadal Germ Cell Tumors: A Multicenter Australian Case Series. Asia-Pacific Journal of Clinical Oncology. 2026;:10.1111/ajco.70083
